Claims for Patent: 6,011,049

Summary for Patent: 6,011,049

Title:	Combinations for diabetes
Abstract:	Combinations of a glitazone antidiabetic agent and a biguanide antidiabetic agent, and optionally a sulfonylurea antidiabetic agent, are useful for treating diabetes mellitus and improving glycemic control.
Inventor(s):	Whitcomb; Randall Wayne (Ann Arbor, MI)
Assignee:	Warner-Lambert Company (Morris Plains, NJ)
Application Number:	09/189,132
Patent Claims:	1. A composition comprising from about 3 mg to about 250 mg of a sulfonylurea antidiabetic agent, from about 5 mg to about 2500 mg of a glitazone antidiabetic agent selected from troglitazone, rosiglitazone and pioglitazone, and from about 300 mg to about 2000 mg of a biguanide antidiabetic agent, said amounts being synergistic in the treatment of non-insulin dependent diabetes mellitus. 2. A composition of claim 1 wherein the sulfonylurea is selected from glisoxepid, glyburide, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, and tolcyclamide. 3. A composition of claim 1 wherein the biguanide is metformin. 4. A synergistic composition comprising from about 100 mg to about 1000 mg of troglitazone, from about 3 mg to about 250 mg of glyburide, and from about 300 mg to about 2000 mg of metformin. 5. A synergistic composition comprising from about 5 mg to about 10 mg of rosiglitazone, from about 3 mg to about 250 mg of a sulfonylurea, and from about 300 mg to about 2000 mg of metformin. 6. A synergistic composition comprising from about 50 mg to about 200 mg of pioglitazone, from about 3 mg to about 250 mg of a sulfonylurea, and from about 300 mg to about 2000 mg of metformin. 7. A method of treating diabetes by administering to a patent in need of treatment from about 3 mg to about 250 mg of a sulfonylurea antidiabetic agent in combination with from about 5 mg to about 2500 mg of a glitazone antidiabetic agent selected from troglitazone, rosiglitazone and pioglitazone and from about 300 mg to about 2000 mg of a biguanide antidiabetic agent, wherein said amounts are synergistic for the treatment of non-insulin dependent diabetes mellitus. 8. A method according to claim 7 wherein the sulfonylurea antidiabetic agent is selected from glisoxepid, glyburide, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbentamide, and tolcyclamide. 9. A method according to claim 8 wherein the glitazone antidiabetic agent is selected from troglitazone, pioglitazone, and rosiglitazone. 10. A method according to claim 8 wherein the biguanide is metformin. 11. A method according to claim 10 wherein the glitazone is troglitazone. 12. A method according to claim 10 wherein the glitazone is rosiglitazone. 13. A method according to claim 10 wherein the glitazone is pioglitazone. 14. A method of treating diabetes by administering to a patient in need of treatment from about 5 mg to about 10 mg of rosiglitazone together with from about 300 mg to about 2000 mg of metformin and from about 3 mg to about 250 mg of a sulfonylurea, wherein said amounts are synergistic for the treatment of non-insulin dependent diabetes mellitus. 15. A method of treating diabetes by administering to a patient in need of treatment from about 100 mg to about 1000 mg of troglitazone together with from about 300 mg to about 2000 mg of metformin and from about 3 mg to about 250 mg of a sulfonylurea, wherein said amounts are synergistic for the treatment of non-insulin dependent diabetes mellitus. 16. A method of treating diabetes by administering to a patient in need of treatment from about 50 mg to about 200 mg of pioglitazone together with from about 300 mg to about 2000 mg of metformin and from about 3 mg to about 250 mg of a sulfonylurea, wherein said amounts are synergistic for the treatment of non-insulin dependent diabetes mellitus.